(NASDAQ: JSPR) Jasper Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Jasper Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast JSPR's revenue for 2025 to be $662,811,424, with the lowest JSPR revenue forecast at $662,811,424, and the highest JSPR revenue forecast at $662,811,424. On average, 3 Wall Street analysts forecast JSPR's revenue for 2026 to be $63,569,641, with the lowest JSPR revenue forecast at $19,583,065, and the highest JSPR revenue forecast at $150,638,960.
In 2027, JSPR is forecast to generate $486,307,755 in revenue, with the lowest revenue forecast at $138,738,482 and the highest revenue forecast at $974,634,071.